BEVERLY, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular...
BEVERLY, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BEVERLY, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- LexaGene...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BEVERLY, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- LexaGene...
BEVERLY, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company...
BEVERLY, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company...
BEVERLY, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company...
BEVERLY, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular...
BEVERLY, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular...
BEVERLY, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene”), a molecular diagnostics company that...